Article Text

Download PDFPDF
Novel GLA T194A variant causes Fabry disease
  1. Maria Nicole Pestana,
  2. Francisca Gomes da Silva,
  3. José Durães and
  4. Gil Silva
  1. Nephrology, Hospital Doctor Nélio Mendonça, Funchal, Portugal
  1. Correspondence to Dr Maria Nicole Pestana; nicole.pest{at}gmail.com

Abstract

Fabry disease (FD) is an X-linked, systemic lysosomal deposition disease caused by alpha-galactosidase A (AGAL) enzyme deficiency deriving out of changes on the GLA gene. Though several mutations have been described, one must consider that even a specific mutation may present with variable clinical expression within the same family. Typically described as a disease that affects hemizygous men with no residual AGAL activity, we describe a novel FD mutation (first case of GLA T194A variant worldwide) in a 49-year-old woman presenting with a classic phenotype of FD. The patient investigation highlighted a previously not described mutation in exon 4 of the GLA gene, as for the substitution of threonine for alanine. The same mutation was identified in her children, one of them presenting with end-stage kidney disease (ESKD) in early adulthood.

  • genetics
  • chronic renal failure

Statistics from Altmetric.com

Footnotes

  • Twitter @nicole.pest@gmail.com

  • Contributors MNP, FGdS, JD and GS all contributed to the planning, conduct and reporting of the work described in the article. JD was the primary physician managing the patient with MNP, FGdS and GS. MNP wrote the main manuscript and collected all informations; FGdS, JD and GS coauthored the manuscript and collected data.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Next of kin consent obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.